• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0
×

Target

Host

Species Reactivity

Species Reactivity

Conjugate

Conjugate

  • HEK293 expressed
  • Endotoxin-free
  • Animal-component free

HumanKine® recombinant human IL-28B protein

Activity

0.07-0.35 ng/mL

Species Reactivity

human

Purity

>95%

Cat no : HZ-1245

Synonyms

Cytokine Zcyto22, IFN lambda 3, IFN lambda 4, IFNL3, IFNL4, IFN-lambda 3, IFN-lambda 4, IL 28B, IL 28C, IL28, IL-28, IL28B, IL-28B, IL28C, Interferon lambda 3, Interferon lambda 4, Interleukin 28B, Interleukin 28C, ZCYTO22

Validation Data Gallery

  • Purity of recombinant human IL-28B was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue.

    Purity of recombinant human IL-28B was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue.

  • Recombinant human IL-28B (HZ-1245) stimulates dose-dependent induction of alkaline phosphatase production in a HEK293 reporter cell line. Alkaline phosphatase production was assessed using pNPP as a chromogenic substrate. The EC50 was determined using a 4-parameter non-linear regression model. The EC50 value range is 0.07-0.35 ng/mL.

    Recombinant human IL-28B (HZ-1245) stimulates dose-dependent induction of alkaline phosphatase production in a HEK293 reporter cell line. Alkaline phosphatase production was assessed using pNPP as a chromogenic substrate. The EC50 was determined using a 4-parameter non-linear regression model. The EC50 value range is 0.07-0.35 ng/mL.

Technical Specifications

GeneID 282617
Species Human
Expression HEK293
Activity 0.07-0.35 ng/mL
Purity >95%
Endotoxin<1 EU/μg
Accession NumberQ8IZI9
Molecular Mass 21 kDa reduced, 19 kDa non-reduced, monomer, non-glycosylated
Formulation 1x PBS, See Certificate of Analysis for details
Species Reactivity human

Stability and Reconstitution

Stability and Storage Lyophilized proteins are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.
Reconstitution Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein to 0.2 mg/mL in sterile 1x PBS pH 7.4 containing 0.1% endotoxin-free recombinant human serum albumin (HSA). Gently swirl or tap vial to mix.

Background

IL28B is a type III IFN, which shares many of the biological effects of type I IFNs but may have fewer side effects due to a more selective receptor distribution. It interacts with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor, beta (IL10RB) and interleukin 28 receptor, alpha (IL28RA) (PMID: 20712453;12469119;16539846).

Synonyms

Cytokine Zcyto22, IFN lambda 3, IFN lambda 4, IFNL3, IFNL4, IFN-lambda 3, IFN-lambda 4, IL 28B, IL 28C, IL28, IL-28, IL28B, IL-28B, IL28C, Interferon lambda 3, Interferon lambda 4, Interleukin 28B, Interleukin 28C, ZCYTO22

Publications

SpeciesTitle

Antiviral Res

Antiviral candidates against the hepatitis E virus (HEV) and their combinations inhibit HEV growth in in vitro.

Authors - Takashi Nishiyama
View Article
human

Cytokine

IFN-λ3 as a host immune response in acute hepatitis E virus infection.

Authors - Kazumoto Murata
View Article
human

J Virol Methods

Screening of novel drugs for inhibiting hepatitis E virus replication.

Authors - Takashi Nishiyama
View Article